APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+16.93%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$4.6B
AUM Growth
+$4.6B
(+5.5%)
Cap. Flow
+$336M
Cap. Flow
% of AUM
7.3%
Top 10 Holdings %
Top 10 Hldgs %
38.55%
Holding
111
New
28
Increased
28
Reduced
21
Closed
14
Top Buys
| 1 |
Eli Lilly
LLY
|
$128M |
| 2 |
Prothena Corp
PRTA
|
$119M |
| 3 |
Akero Therapeutics
AKRO
|
$106M |
| 4 |
Sarepta Therapeutics
SRPT
|
$105M |
| 5 |
Axsome Therapeutics
AXSM
|
$68.7M |
Top Sells
| 1 |
AstraZeneca
AZN
|
$161M |
| 2 |
Johnson & Johnson
JNJ
|
$160M |
| 3 |
McKesson
MCK
|
$127M |
| 4 |
UnitedHealth
UNH
|
$124M |
| 5 |
AbbVie
ABBV
|
$116M |
Sector Composition
| 1 | Healthcare | 96.68% |
| 2 | Financials | 0.52% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITCI
26
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $65.3M | 1.33% |
1,402,500
+626,996
| +81% | +$29.2M |
|
|
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
| $61M | 1.24% |
445,500
-104,500
| -19% | -$14.3M |
|
28
Bio-Rad Laboratories Class A
BIO
$7.76B
| $60.4M | 1.23% |
+144,800
| New | +$60.4M |
|
29
Alnylam Pharmaceuticals
ALNY
$58.4B
| $57.7M | 1.17% |
+288,500
| New | +$57.7M |
|
30
Apellis Pharmaceuticals
APLS
$3.51B
| $57.6M | 1.17% |
844,000
+629,000
| +293% | +$43M |
|
31
Intellia Therapeutics
NTLA
$1.25B
| $55.9M | 1.14% |
999,100
-126,094
| -11% | -$7.06M |
|
32
IDEAYA Biosciences
IDYA
$2.25B
| $55.4M | 1.13% |
3,715,400
+742,453
| +25% | +$11.1M |
|
33
Kezar Life Sciences
KZR
$28.6M
| $46.6M | 0.95% |
5,414,400
+1,364,400
| +34% | +$11.7M |
|
|
BLU
34
DELISTED
BELLUS Health Inc.
BLU
| $45.9M | 0.93% |
4,346,700
+81,700
| +2% | +$863K |
|
35
Revolution Medicines
RVMD
$7.42B
| $45.8M | 0.93% |
2,321,200
+996,200
| +75% | +$19.6M |
|
36
Avidity Biosciences
RNA
$6.03B
| $42.5M | 0.86% |
2,600,000
+519,800
| +25% | +$8.49M |
|
37
Jazz Pharmaceuticals
JAZZ
$7.94B
| $42.4M | 0.86% |
318,300
+256,300
| +413% | +$34.2M |
|
38
Zai Lab
ZLAB
$3.48B
| $42.2M | 0.86% |
+1,234,000
| New | +$42.2M |
|
39
Arrowhead Research
ARWR
$3.74B
| $41.5M | 0.84% |
1,255,374
-183,625
| -13% | -$6.07M |
|
40
Pliant Therapeutics
PLRX
$103M
| $41.4M | 0.84% |
+1,981,100
| New | +$41.4M |
|
41
DexCom
DXCM
$30.1B
| $37.7M | 0.77% |
+467,600
| New | +$37.7M |
|
42
Stryker
SYK
$147B
| $37.4M | 0.76% |
+184,700
| New | +$37.4M |
|
|
VERV
43
DELISTED
Verve Therapeutics
VERV
| $35.8M | 0.73% |
+1,042,706
| New | +$35.8M |
|
44
Altimmune
ALT
$327M
| $34.3M | 0.7% |
2,684,000
-297,000
| -10% | -$3.79M |
|
45
Centene
CNC
$14.6B
| $33.6M | 0.68% |
+432,400
| New | +$33.6M |
|
46
Caribou Biosciences
CRBU
$175M
| $33.5M | 0.68% |
3,172,600
+222,600
| +8% | +$2.35M |
|
|
47
AstraZeneca
AZN
$253B
| $30.9M | 0.63% |
563,200
-2,935,800
| -84% | -$161M |
|
|
NGM
48
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $23.5M | 0.48% |
+1,798,100
| New | +$23.5M |
|
|
DCPH
49
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $22M | 0.45% |
1,191,800
-8,200
| -0.7% | -$152K |
|
|
PNT
50
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $21.8M | 0.44% |
+2,820,000
| New | +$21.8M |
|